Peter Pitts was appointed as Director at BRAINSTORM CELL THERAPEUTICS INC..
“appointed Peter Pitts to serve as a director of the Company, effective as of the same day”
BRAINSTORM CELL THERAPEUTICS INC. — fact timeline
Source-grounded facts extracted from BRAINSTORM CELL THERAPEUTICS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BRAINSTORM CELL THERAPEUTICS INC. reported the full year ended December 31, 2025 results: net income Net loss for the twelve months ended December 31, 2025, was approximately $10.3 million, EPS Net loss per share for the twelve months ended December 31, 2025, and 2024 was $1.11 and $2.31, respectively.
“On March 31, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with an accredited investor valued at $1,000,000 (effective 2026-02-24).
“On February 24, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ). The transaction will occur in up to eight closings. The aggregate subscription amount under the Purchase Agreement is $1,000,000, consisting of $125,000 at the first closing and an additional $875,000 on up to seven additional closings.”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with an accredited investor valued at $1,000,000 (effective 2026-02-09).
“On February 9, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”), pursuant to which the Company agreed to sell, in a private placement, shares of its common stock, par value $0.00005 per share (the “ Common Stock ”), and, in lieu of shares as elected by an investor, pre-funded warrants to purchase Common Stock (the “ Pre-Funded Warrants ).”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Auctus Fund, LLC valued at aggregate principal amount of $140,000 (effective 2026-01-06).
“On January 6, 2026, the Company entered into a Securities Purchase Agreement with Auctus Fund, LLC, under which the Company issued a convertible promissory note in the aggregate principal amount of $140,000, including a $14,000 original issue discount, for cash proceeds of $126,000”
BRAINSTORM CELL THERAPEUTICS INC. entered into Note Purchase Agreement with Quick Capital, LLC valued at principal amount of $94,875 (effective 2026-01-05).
“On January 5, 2026, the Company entered into a Note Purchase Agreement with Quick Capital, LLC, under which the Company issued a convertible promissory note in the principal amount of $94,875”
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Vanquish Funding Group Inc. valued at aggregate principal amount of $94,300 (effective 2025-12-31).
“On December 31, 2025, the Company entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., under which the Company issued a note in the aggregate principal amount of $94,300 (including $12,300 original issue discount) for aggregate purchase price proceeds of $82,000”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“July 16, 2025, Brainstorm Cell Therapeutics Inc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of trading on July 18, 2025. The Company has applied and been approved to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.
“January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company t”
BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company reque”
Hartoun Hartounian was appointed as Executive Vice President and Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS INC..
“On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.